Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
about
Lung microbiology and exacerbations in COPDAntibiotics for exacerbations of chronic obstructive pulmonary diseaseProphylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD)Positioning new pharmacotherapies for COPDTreatment of patients with COPD and recurrent exacerbations: the role of infection and inflammationEvidence synthesis for count distributions based on heterogeneous and incomplete aggregated data.Chronic obstructive pulmonary disease exacerbations: latest evidence and clinical implications.Lower airway colonization and inflammatory response in COPD: a focus on Haemophilus influenzaeGlobal Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.Efficacy and safety of moxifloxacin in acute exacerbations of chronic bronchitis: a prospective, multicenter, observational study (AVANTI)Genomic Investigations unmask Mycoplasma amphoriforme, a new respiratory pathogen.A double-blind, randomised, placebo-controlled study of roxithromycin and doxycycline combination, roxithromycin alone, or matching placebo for 12 weeks in adults with frequent exacerbations of chronic obstructive pulmonary disease.Randomised, double-blind, placebo-controlled trial with azithromycin selects for anti-inflammatory microbial metabolites in the emphysematous lungEffects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trialClinical impact of chronic obstructive pulmonary disease on non-cystic fibrosis bronchiectasis. A study on 1,790 patients from the Spanish Bronchiectasis Historical Registry.Determinants of bacteriological outcomes in exacerbations of chronic obstructive pulmonary disease.Effect of Fluoroquinolones and Macrolides on Eradication and Resistance of Haemophilus influenzae in Chronic Obstructive Pulmonary DiseaseGuidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations.Effect of levofloxacin on neutrophilic airway inflammation in stable COPD: a randomized, double-blind, placebo-controlled trial.Acute Exacerbation and Respiratory InfectionS in COPD (AERIS): protocol for a prospective, observational cohort study.The Saudi Guidelines for the Diagnosis and Management of COPD.Prophylactic antibiotic therapy in chronic obstructive pulmonary disease.The benefits of long-term systemic antimicrobial therapy in chronic obstructive pulmonary disease.The use of moxifloxacin for acute exacerbations of chronic obstructive pulmonary disease and chronic bronchitis.What is in the guidelines about the pharmacological treatment of chronic obstructive pulmonary disease?COPD updates: what's new in pathophysiology and management?New anti-inflammatory targets for chronic obstructive pulmonary disease.Defining phenotypes in COPD: an aid to personalized healthcare.Pharmacotherapy for lower respiratory tract infections.An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease.Long-term azithromycin therapy in patients with severe COPD and repeated exacerbationsPrevention of infections in nursing homes: antibiotic prophylaxis versus infection control and antimicrobial stewardship measures.Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?Nontypeable Haemophilus influenzae and chronic obstructive pulmonary disease: a review for clinicians.Treatment options for moderate-to-very severe chronic obstructive pulmonary disease.Antibiotics for acute and chronic respiratory infection in patients with chronic obstructive pulmonary disease.Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease.An update on the pharmacotherapeutic management of lower respiratory tract infections.Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.Prevention of Exacerbations in Chronic Obstructive Pulmonary Disease: Knowns and Unknowns.
P2860
Q22305860-01C741E0-4347-4117-B32C-86BA5DDC5CBFQ24202248-E0D3C1C7-5BE9-4766-AF11-DFBA57E330ACQ24202329-650F6FE3-EAC2-49BA-B58A-FE11A4C58CF3Q26798659-B7284985-C9C4-4ACA-9D31-58347CB0DD42Q28071694-66E46D5D-2250-4197-AA56-FBF8837FBF10Q30949429-79692EEC-4614-46B3-B959-998F8332432EQ34039712-312327FB-574B-46F8-A8B8-F95AEA54369BQ34386841-43EFD3BC-C3D1-4A64-88B8-CCDDB12F04EBQ34550471-AE6B2DDB-957D-4143-BD6B-B1DDB5889E62Q34560033-D5DFF241-9AF7-45C1-A023-C609D754247BQ34946001-AB9287EA-EFB0-417F-A9AE-C9278D473BC7Q36035081-2A136719-4C71-4426-BBC9-5DA1A75F3CE7Q36093531-BF0AB32D-FCE4-4A73-8DF8-F8F36098DBD7Q36150134-F04C0A08-9B58-4D2F-8D7A-9951EE68DA60Q36380278-049507D1-A2B7-49E3-81A5-09459108F618Q36526951-73F54EE0-FBB6-4DC1-BC14-8588078B31DBQ37023332-79849529-7FE3-4801-B617-409A07AFAE06Q37177278-28F71B70-0DD8-4CE4-8E42-6574C5D9BBDEQ37582484-0869F1BF-4EA3-44DF-9BDC-DBEC517A6BEAQ37628494-C05613D7-76F5-4200-B5AF-BD135DDE78D4Q37733309-777E3FD6-2702-428A-BD4B-63D0F98FBA73Q37763372-A0C79D78-3B15-446E-AEEA-6D549A91C472Q37850201-FE40625C-26F6-4088-99F4-634A01D28D24Q38056764-67F1EE97-F808-4129-AC66-813EEB88A63EQ38095562-A15B64C0-CD30-4E80-ADC4-FD36A8A17621Q38130515-3A603EA9-9C84-4339-8502-605023E180A7Q38131512-0C4E28ED-F652-45E5-B4FD-2BE58EE9F3A8Q38208244-77813DF9-6CAD-47AF-800F-E097A9EB962AQ38248719-45EAD41A-6166-41CC-A83D-A7639BEE65EFQ38399184-65993094-7DA6-4C5C-BB95-DF0854A22CB5Q38624850-465E932D-6FBA-4ABF-84DE-7E78A5704AA1Q38665838-8DF18FB7-C1C8-450E-B6B0-2DB6A4A4986CQ38667550-D38F9CE4-0F63-4D94-B22A-6980C94621B2Q38679715-2705E303-D9AD-4E07-9058-6F5D3DDADA12Q38740756-1AB11EB9-5951-4872-BEEB-152F803B9B8CQ39370816-A502C05D-83E7-4E27-8A07-0AF6A9887FFFQ40106829-4B5B07E7-8EF7-4D1B-A245-A0632BB1DE80Q40222424-9C67C1E7-82CD-4B08-958F-51067E8726F0Q41071899-261DFA8B-701F-4F5A-9DC6-20CF374BE8B2Q41400495-9484FD20-0B83-450C-BCC9-CB9AB4888FA2
P2860
Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@ast
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@en
type
label
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@ast
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@en
prefLabel
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@ast
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@en
P2093
P2860
P356
P1433
P1476
Pulsed moxifloxacin for the pr ...... a randomized controlled trial.
@en
P2093
Ethan Rubinstein
Jadwiga A Wedzicha
Marlize Schmitt Theron
PULSE Study group
Paul W Jones
Robert Wilson
Sanjay Sethi
P2860
P2888
P356
10.1186/1465-9921-11-10
P577
2010-01-28T00:00:00Z
P5875
P6179
1030971985